Advertisement

The prevalence of systemic sclerosis is increased among patients with alopecia areata: a population-based study

  • Khalaf KridinEmail author
  • Dana Tzur Bitan
  • Doron Comaneshter
  • Arnon D. Cohen
Original Article
  • 23 Downloads

Abstract

Although the coexistence of alopecia areata (AA) and systemic sclerosis (SSc) has been anecdotally reported, the association between these conditions has been poorly investigated. We aimed to assess the association between AA and SSc using a large-scale real-life computerized database. A cross-sectional study was conducted comparing the prevalence of SSc among patients with AA and among age-, sex-, and ethnicity-matched control subjects. Chi-square and t tests were used for univariate analysis, and logistic regression model was used for multivariate analysis. The study was performed utilizing the computerized database of Clalit Health Services ensuring 4.4 million subjects. A total of 51,561 patients with AA and 51,410 controls were included in the study. The prevalence of SSc was increased in patients with AA as compared with the control group (0.1% vs. 0.0%, respectively; OR, 2.30; 95% CI, 1.2–4.4; P = 0.010). The association was stronger among older and Jewish patients. In a multivariate analysis adjusting for sex, age, ethnicity, and other comorbidities, AA was still independently associated with SSc (OR, 2.3; 95% CI, 1.2–4.4; P = 0.012). In conclusion, a significant positive association was revealed between AA and SSc. Further studies are necessary to establish these findings in other study populations and to elucidate the mechanism underlying this association. Awareness of SSc may be of importance for physicians treating patients with AA, and screening for SSc in patients with relevant symptoms may be considered.

Keywords

Alopecia areata Systemic sclerosis Patients 

Notes

Compliance with ethical standards

Conflict of interest

ADC served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. None of the other authors have any conflicts of interest to declare.

References

  1. 1.
    Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;24(8):397–403.  https://doi.org/10.2147/CCID.S53985.
  2. 2.
    Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16(1):S25–7.CrossRefGoogle Scholar
  3. 3.
    Biran R, Zlotogorski A, Ramot Y. The genetics of alopecia areata: new approaches, new findings, new treatments. J Dermatol Sci. 2015;78(1):11–20.  https://doi.org/10.1016/j.jdermsci.2015.01.004.CrossRefGoogle Scholar
  4. 4.
    Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):466–477.e16.CrossRefGoogle Scholar
  5. 5.
    Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15(5):417–26.CrossRefGoogle Scholar
  6. 6.
    The Lancet. Systemic sclerosis: advances and prospects. Lancet. 2017;7;390(10103):1624.Google Scholar
  7. 7.
    Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015 ;15(6):167.Google Scholar
  8. 8.
    Czirják L, Foeldvari I, Müller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (United Kingdom). 2008;47 Suppl 5:v44–5.CrossRefGoogle Scholar
  9. 9.
    Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001 [cited 2017 Jan 30];3:404–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11433630.
  10. 10.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic dis. 1987;40:373–83 Available from: http://www.ncbi.nlm.nih.gov/pubmed/3558716.CrossRefGoogle Scholar
  11. 11.
    Watad A, Bragazzi NL, Adawi M, Aljadeff G, Amital H, Comaneshter D, et al. Anxiety disorder among rheumatoid arthritis patients: insights from real-life data. J Affect Disord. 2017;213:30–4.CrossRefGoogle Scholar
  12. 12.
    Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology. 2006;17:202–17.CrossRefGoogle Scholar
  13. 13.
    Szyper-Kravitz M, Marai I, Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity. 2005;38:247–55.CrossRefGoogle Scholar
  14. 14.
    Davidson A, Diamond B. Autoimmune diseases. New Engl J Med. 2001;345:340–50 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11484692.CrossRefGoogle Scholar
  15. 15.
    Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24–32.CrossRefGoogle Scholar
  16. 16.
    Seo HM, Han SS, Kim JS. Cancer risks among patients with alopecia areata: a population-based case-control study in Korea. J Am Acad Dermatol. 2018;78(1):209–211.CrossRefGoogle Scholar
  17. 17.
    Serarslan G, Savaş N, Yenin JZ. Is atopy and autoimmunity more prevalent in patients with alopecia areata? A comparative study. J Eur Acad Dermatol Venereol. 2012;26(6):720–3.CrossRefGoogle Scholar
  18. 18.
    Thomas E, Kadyan R. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008;53(2):70–4.CrossRefGoogle Scholar
  19. 19.
    Robinson D, Eisenberg D, Nietert PJ, Doyle M, Bala M, Paramore C, et al. Systemic sclerosis prevalence and comorbidities in the US, 2001–2002. Curr Med Res Opin. 2008;24(4):1157–66.CrossRefGoogle Scholar
  20. 20.
    Watad B, McGonagle D, Comaneshter C, et al. Systemic sclerosis is linked to psoriasis and may impact on patients’ survival: a large cohort study. J Clin Med. 2019;8(4):521.CrossRefGoogle Scholar
  21. 21.
    Thompson DM, Robinson TW, Lennard-Jones J. Alopecia areata, vitiligo, scleroderma and ulcerative colitis. Proc R Soc Med. Royal Society of Medicine Press; 1974 [cited 2019 Jul 31];67:1010–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4154458.
  22. 22.
    Shellow Wvr, Edwards Je, Koo Jym. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992 [cited 2019 Jul 31];31:186–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1568816.CrossRefGoogle Scholar
  23. 23.
    Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65(5):949–56.CrossRefGoogle Scholar
  24. 24.
    Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61(4):581–91.CrossRefGoogle Scholar
  25. 25.
    Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117(8):2019–27.CrossRefGoogle Scholar
  26. 26.
    Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol. 2008;35(9):1809–11.Google Scholar
  27. 27.
    Oliver SJ. The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide. Curr Rheumatol Rep. 2000;2(6):486–91.CrossRefGoogle Scholar
  28. 28.
    O’Reilly S, Hügle T, Van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (United Kingdom). 2012;51(9):1540–9.CrossRefGoogle Scholar
  29. 29.
    Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;1;466(7302):113–7.CrossRefGoogle Scholar
  30. 30.
    Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis. 2013;72(7):1233–8.CrossRefGoogle Scholar
  31. 31.
    Ramos PS, Silver RM, Feghali-Bostwick CA. Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol. 2015;27(6):521–9.CrossRefGoogle Scholar
  32. 32.
    Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998;110(2):103–9.CrossRefGoogle Scholar
  33. 33.
    Höfler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol. 2005;2:11. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1291382&tool=pmcentrez&rendertype=abstract.CrossRefGoogle Scholar
  34. 34.
    Birkenfeld S, Dreiher J, Weitzman D, Cohen AD. Coeliac disease associated with psoriasis. Br J Dermatol. 2009;161:1331–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19785615.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of DermatologyRambam Health Care CampusHaifaIsrael
  2. 2.Department of Behavioral SciencesAriel UniversityArielIsrael
  3. 3.Siaal Research Center for Family Medicine and Primary Care, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael
  4. 4.Department of Quality Measurements and Research, Chief Physician’s OfficeClalit Health ServicesTel AvivIsrael

Personalised recommendations